Mutant TEM β-lactamase producing resistance to ceftazidime, ampicillins, and β-lactamase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 646-653

  Vakulenko, Sergei ^a   Golemi, Dasantila ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CLAVULANIC ACID; TAZOBACTAM;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; DNA SEQUENCE; ENZYME ISOLATION; ENZYME KINETICS; ENZYME METABOLISM; GENE MUTATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; AMPICILLIN RESISTANCE; BETA-LACTAMASES; CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CLONING, MOLECULAR; CULTURE MEDIA; DNA, BACTERIAL; ENZYME INHIBITORS; INDICATORS AND REAGENTS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHENOTYPE; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036173371     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.646-653.2002     Document Type: Article

References (44)

1. Nucleotide sequences of the genes coding for the TEM-like β-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2)
2. Characterization of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli
3. β-Lactamase mutations far from the active site influence inhibitor binding
4. Construction and characterization of an OHIO-1 β-lactamase bearing Met69-e and Gly238Ser mutations
5. Inhibitor-resistant TEM (IRT) β-lactamases with different substitutions at position 244
6. Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 β-lactamase produced by Proteus mirabilis strains
7. Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to β-lactamase inhibitors
8. A functional classification scheme for β-lactamases and its correlation with molecular structure
9. How β-lactamases have driven pharmaceutical drug discovery: From mechanistic knowledge to clinical circumvention
10. Properties of IRT-14 (TEM-45), a newly characterized mutant of TEM-type β-lactamases
11. Sequences of CAZ-3 and CTX-2 extended-spectrum β-lactamase genes
12. Survey of prevalence of extended-spectrum β-lactamases among Enterobacteriaceae
13. Site-directed mutagenesis at the active site of Escherichia coli TEM-1 β-lactamase: Suicide inhibitor-resistant mutants reveal the role of arginine-244 and methionine-69 in catalysis
14. The determination of enzyme-inhibitor constant
15. A novel complex mutant β-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum β-lactamase-producing klebsiellae
16. A graphical method for extracting rate constants from some enzyme-catalyzed reactions not monitored to completion
17. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM β-lactamases from clinical isolates of Escherichia coli
18. Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France
19. Evolution and spread of SHV extended-spectrum β-lactamases in gram-negative bacteria
20. Amino acid sequence determinants of β-lactamase structure and activity
21. Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 β-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime
22. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: Mutations, specificity, and three-dimensional structure
23. The analysis of enzyme progress curves by numerical differentiation, including competitive product inhibition and enzyme reactivation
24. First characterization of inhibitor-resistant TEM (IRT) β-lactamases in Klebsiella pneumoniae strains
25. Evolution of antibiotic resistance: Several different amino acid substitutions in an active site loop alter the substrate profile of β-lactamase
26. Multiple substitutions at position 104 of β-lactamase TEM-1: Assessing the role of this residue in substrate specificity
27. Origin and impact of plasmid-mediated extended-spectrum β-lactamases
28. Emergence of an inhibitor-resistant β-lactamase (SHV-10) derived from an SHV-5 variant
29. Clinical significance of extended-spectrum β-lactamases
30. The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the β-lactamase resistance to clavulanic acid
31. Extended-spectrum plasmid-mediated β lactamases
32. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate
33. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli
34. Construction and characterization of mutants of the TEM-1 β-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to β-lactamase inhibitors
35. DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution
36. Rapid evolution of a protein in vitro by DNA shuffling
37. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 β-lactamase: Direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid
38. Selection and characterization of β-lactam-β-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 β-lactamase gene
39. pUC19 β-lactamase from Escherichia coli
40. Directed evolution of ampicillin-resistant activity from a functionally unrelated DNA fragment: A laboratory model of molecular evolution
41. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhibitors